NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study (AFTX)
Sponsor: Biosense Webster, Inc.
Terminated
Enrollment stopped after CDRH Advisory Panel (Nov 20, 2008) recommended NAVISTAR® THERMOCOOL® catheter approval.
Other terminated trials from Biosense Webster, Inc.
- Non-ischemic Cardiomyopathy · Nov 2024
- Ventricular Tachycardia · Phase EARLY_PHASE1 · Oct 2024
- Stroke · Phase PHASE3 · Dec 2023
- Atrial Fibrillation · Phase NA · Jun 2023
- Paroxysmal Atrial Fibrillation · Phase NA · Oct 2022
More terminations from Biosense Webster, Inc.
Other Arrhythmia trials with similar outcome
This PHASE3 trial investigates Arrhythmia and Atrial Fibrillation and is currently terminated or withdrawn. Biosense Webster, Inc. leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biosense Webster, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.